EIKO LIFESCIENCES MD, chairman, board of directors and AGM
BSE: 540204Chemicals & PetrochemicalsSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹49.11.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹74 Cr3,149th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 1.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 9.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.07
- Volume, BSEVolume. Shares traded on the last trading day.
- 21,594
EIKO LIFESCIENCES board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonLAXMIKANT RAMPRASAD KABRA
- Company Secretary and Compliance OfficerChintan Doshi
6 directors3 independent1 executive2 non-executive
- LAXMIKANT RAMPRASAD KABRA · ChairpersonNon-executive · joined Aug 2013 · 1 listed board · 2 committee seats
- BHAVESH DHIRAJLAL TANNANon-executive · joined Aug 2013 · 1 listed board
- RAJKUMAR GOVINDAS BAHETIIndependent · joined Feb 2021 · reappointed Feb 2026 · 67 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- KAJAL DHANPATRAJ KOTHARIIndependent · joined Sep 2020 · reappointed Sep 2025 · 72 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- SUMUKH PRABHAKAR VARTAKExecutive · joined Jul 2025 · 1 listed board
- SURAJ MAHADEV GAIKWADIndependent · joined Aug 2026 · 1 month as independent · 2 listed boards · 2 as independent · 1 committee seat
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- HASTI ARJAV DOSHI, left 24 Aug 2026: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 24 Sep 20266 of 6 present3 independent · 30 days in between
- 24 Aug 20266 of 6 present3 independent · 11 days in between
- 12 Aug 20266 of 6 present3 independent · 77 days in between
- 26 May 20266 of 6 present3 independent
Audit Committee
Chair RAJKUMAR GOVINDAS BAHETI
LAXMIKANT RAMPRASAD KABRA, KAJAL DHANPATRAJ KOTHARI
- 12 Aug 20263 of 3 present2 independent · 77 days in between
- 26 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair RAJKUMAR GOVINDAS BAHETI
LAXMIKANT RAMPRASAD KABRA, KAJAL DHANPATRAJ KOTHARI
- 24 Aug 20263 of 3 present2 independent · 89 days in between
- 26 May 20263 of 3 present2 independent
Stakeholders Relationship Committee
Chair KAJAL DHANPATRAJ KOTHARI
LAXMIKANT RAMPRASAD KABRA, RAJKUMAR GOVINDAS BAHETI
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- PSV Jain And AssociatesPeer-review certificate valid to Apr 2029
1 earlier auditor
- PSV JAIN & ASSOCIATESNamed in the filing for the quarter to Sep 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
EIKO LIFESCIENCES AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.EIKO LIFESCIENCES dividend history
Annual general meeting, 22 Sep 2026
3,076 shareholders on the register on 16 Sep 2026; present: 5 promoters and 20 others; votes counted by SHRAVAN A. GUPTA / SHRAVAN A. GUPTA & ASSOCIATES.The company's voting result (opens in a new tab)
To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2026 together with the Reports of the Board of Directors and Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To re-appoint Mr. Bhavesh Dhirajlal Tanna (DIN: 03353445) as a "Director", liable to retire by rotation, who has offered himself for re- appointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 42.36% · promoters 0.00% · institutions 0.00% · other public 100.00%
- To appoint Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as an Independent Director of the company.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To approve Material Related Party Transactions entered into or proposed to be entered into with related parties, in accordance with applicable laws and regulations.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 42.36% · promoters 0.00% · institutions 0.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Jun 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere | Reason and comments |
|---|---|---|---|---|---|---|
| Preferential IssuesFeb 2026 | 4.06 | – | – | No | Audit committee: The Company has allotted 29,50,000 (Twenty Nine Lakh Fifty Thousand) Warrants convertible into equivalent number of Equity Shares to the persons belonging to Promoter and Promoter Group on Preferential Basis, at an issue price of Rs. 55/- per warrant, including premium of Rs. 45/- per warrant, against which 25% of the consideration has been received on application, dated 24 February, 2026. In Current quarter no conversion of warrant has been done.MoreLess |